Zhaoke Ophthalmology Limited (HKG:6622)

Hong Kong · Delayed Price · Currency is HKD

2.630

-0.050 (-1.87%)

Jun 18, 2026, 11:48 AM HKT

-10.54% (1Y)

Market Cap	1.47B +20.8%
Revenue (ttm)	35.58M -53.9%
Net Income	-232.56M
EPS	-0.43
Shares Out	548.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,500
Open	2.680
Previous Close	2.680
Day's Range	2.630 - 2.680
52-Week Range	2.380 - 4.600
Beta	1.09
Analysts	Strong Buy
Price Target	2.65 (+0.76%)
Earnings Date	Aug 28, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 276

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6622

Full Company Profile

Financial Performance

In 2025, Zhaoke Ophthalmology's revenue was 31.97 million, a decrease of -53.88% compared to the previous year's 69.32 million. Losses were -208.98 million, -12.00% less than in 2024.

Financial numbers in CNY Financial Statements